本报（chinatimes.net.cn）记者于娜 北京报道 备受市场关注的青少年近视防控赛道大战在即，兴齐眼药再添新筹码却腹背受敌。 近日，兴齐眼药（300573.SZ）公告硫酸阿托品滴眼液新规格获批。此次新增规格与现有产品形成梯度 布局，可实现精准防控，契合青少年近视防控市场需求，但公司核心产品依赖、研发乏力等隐忧仍存， 叠加市场竞争升温，增长挑战重重。 公开信息显示，硫酸阿托品滴眼液新规格针对6—12岁、球镜度数-1.00D至-4.00D近视儿童，可解决单 一浓度适配性不足的痛点。公告发布后，公司股价随即小幅上涨，反映出资本市场对其商业化前景的期 待。国信证券测算，当前中国儿童青少年近视率超50%，该领域渗透率达20%时，市场规模将接近190 亿元，市场空间广阔。 不过，利好背后暗藏隐忧。新规格获批虽能短期提振业绩，却无法根治兴齐眼药产品结构单一、研发管 线薄弱的核心问题；同时，竞品技术迭代、行业政策调整及产品学术争议等变量，均可能制约其市场拓 展，为后续发展埋下隐患。 大单品依赖困局 此次新规格获批进一步强化了硫酸阿托品滴眼液在兴齐眼药营收体系中重量级的地位，但也让兴齐眼 药"押注单一产品"的经营风险 ...

尊敬的 合作伙伴及广大消费者 ： 为科学评估青少年近视管理产品的实际使用效果，更好地为广大青少年视力健康服务，江苏格林视 通光学与艾瑞咨询正式达成战略合作，共同开展 "格林视通青少年近视管理镜片用户体验追踪调 研"项目。 【调研目的】 本次合作旨在通过专业的第三方市场研究方法，收集格林视通青少年近视管理镜片（包括新知控 MAX、新知控PRO等产品）的真实使用数据，客观评估产品在青少年近视防控中的实际效果，为 产品持续优化和行业健康发展提供科学依据。 【调研范围】 【数据安全与隐私保护承诺】 【专业性保障】 艾瑞咨询将采用科学的抽样方法、标准化的数据采集流程及严谨的统计分析技术，确保调研结果的 客观性、准确性与可靠性。调研过程接受双方联合监督，最终报告将由艾瑞咨询独立出具。 【共同愿景】 双方希望通过此次合作，以真实数据说话，以专业态度做事，为青少年近视防控事业贡献一份力 量，让更多家庭了解科学的近视管理方法，让更多孩子拥有清晰光明的未来。 江苏格林视通光 学 消费者端：已使用格林视通青少年近视管理镜片的消费者家长 渠道端：格林视通合作零售商、经销商、代理商门店 本次调研由艾瑞咨询独立执行，遵循国际市场研究行业 ...

Core Viewpoint - The event "EYE护视界 阅见未来" organized by Zeiss Optical, Sun Yat-sen University Eye Center, and Guangzhou Library focuses on public health issues related to myopia prevention among youth, promoting early screening and intervention for eye health [1][4]. Group 1: Event Overview - The event took place on September 14 at Guangzhou Library, featuring interactive zones where parents and children could learn about eye health and myopia prevention [1]. - The collaboration includes the establishment of a "Healthy Reading Promotion Practice Base" to enhance awareness and education on eye health [2]. Group 2: Expert Contributions - Professor Yang Xiao from Sun Yat-sen University emphasized the importance of early establishment of refractive development records for children and creating a suitable reading environment [3]. - Zeiss Optical's market manager highlighted the company's commitment to innovation in technology and services for lifelong eye health management [3]. Group 3: Community Engagement - The event provided free vision checks using professional equipment, reinforcing the concept of "early screening, early protection" [4]. - Interactive activities aimed to engage children in understanding the importance of eye protection, showcasing Zeiss's dedication to social responsibility and community health [4]. Group 4: Future Directions - Zeiss Optical plans to continue collaborating with various stakeholders to enhance eye health management solutions and promote a sustainable public health network [4].

Group 1 - The article highlights the rising costs and pressures faced by parents regarding their children's health, particularly in managing myopia, dental issues, and height concerns [2][57] - A significant market has emerged around myopia treatment, with the overall myopia rate among children and adolescents in China reaching 52.7%, indicating that one in two children is affected [27][28] - Companies in the myopia treatment sector, such as Opcon Vision and Aier Eye Hospital, are experiencing substantial revenue growth, with Opcon Vision's revenue reaching 1.814 billion and Aier Eye Hospital's revenue at 20.983 billion [30][31] Group 2 - The orthodontics market is also booming, with companies like Times Angel and Invisalign dominating the space, capturing significant market shares and generating substantial revenues [43][44] - The article discusses the high costs associated with dental treatments, with some families spending up to 60,000 on orthodontic solutions, reflecting a growing trend in dental care for children [34][36] - The prevalence of dental issues among children is alarming, with a reported 67.82% incidence of malocclusion, leading to increased demand for orthodontic services [41] Group 3 - Height management is emerging as a new area of concern for parents, with the market for growth hormone treatments and related products projected to reach 8-12 billion, growing at a compound annual growth rate of over 25% [56][57] - Companies like Jinsai Pharmaceutical are leading the growth in the height management sector, with a reported revenue of 10.67 billion, indicating a strong market presence [56] - The societal pressures regarding height are reflected in the increasing willingness of parents to invest heavily in treatments, with some spending tens of thousands on growth hormone therapies [48][49]

Core Viewpoint - The acquisition of 75% equity in Shanyang Qicheng Hospital Management Co., Ltd. for 334 million yuan by Opcon Vision reflects the company's need for business transformation and new growth opportunities amid declining performance in its core OK lens market [1][2]. Financial Performance - In 2024, Opcon Vision reported revenue of 1.814 billion yuan, a year-on-year increase of 4.4%, while net profit attributable to shareholders was 572 million yuan, down 14.16% [1]. - For Q1 2025, the company achieved revenue of 478 million yuan, a 2.95% increase year-on-year, but net profit fell by 16.93% to 160 million yuan [1]. - The sales revenue from hard contact lenses, primarily OK lenses, was 760 million yuan in 2024, representing a decline of 6.73% [1][9]. Strategic Acquisition - The acquisition of Shanyang Qicheng, established in May 2024, is seen as a strategic move to extend into the downstream medical services sector, aiming to create a complete industry chain from products to services [2][3]. - The assessed value of Shanyang Qicheng's equity is 454 million yuan, with a significant appreciation of 771.49% over its book net assets [3]. Funding and Investment Concerns - The acquisition funding of 334 million yuan primarily comes from the company's 2022 private placement, originally intended for community eye care service terminal construction, which has seen only 10% of the planned investment completed by the end of 2024 [4]. - The slow progress of the original project raises concerns about the efficiency of fund utilization [4]. Market Position and Strategy - The acquisition is expected to help Opcon Vision consolidate and expand its market share in the Southwest region, reducing reliance on the highly competitive East China market [5]. - The business structure of Shanyang Qicheng includes approximately 40% of refractive surgery and 14% related to OK lenses, aligning well with Opcon Vision's existing product line [5][10]. Performance Guarantees - The acquisition includes a 10-year performance commitment, with net profit targets set for 2025-2029, requiring significant growth compared to 2024's net profit of 30.58 million yuan [6]. - The long-term performance commitments reflect the company's high expectations for the acquisition while implementing strict risk control measures [6]. Industry Trends - The youth myopia prevention market in China is undergoing significant changes, with a reported overall myopia rate of 52.7% among children and adolescents [7]. - The competitive landscape for OK lenses has intensified, with over 20 registered products leading to price competition and a shift towards alternative solutions like defocus glasses [9][10]. Long-term Outlook - The demand for professional vision health services is expected to grow, driven by the "Healthy China" strategy and increasing health awareness among parents [11].

Group 1 - The core viewpoint emphasizes the importance of controlling the progression of myopia in children rather than attempting to reverse it, as most optical methods can only slow down the increase in myopia [2][3] - For children around the age of 10 with myopia under 100 degrees, optical methods like functional frame glasses and OK lenses may show some cases of myopia regression, but this is not common [2] - It is crucial to conduct cycloplegic refraction tests to accurately assess myopia, as traditional vision tests may not detect low degrees of myopia in children who still have normal visual acuity [3] Group 2 - For children who have already developed myopia, intervention measures should be tailored based on the degree of myopia and astigmatism, as well as the individual child's situation [3] - Functional frame glasses or OK lenses are recommended for children with relatively low myopia and high astigmatism, but adjustments should be made based on the child's response and axial growth [3] - Children with low myopia or pure astigmatism may be better suited to wear frame glasses [3]

Core Viewpoint - Myopia among adolescents has become a global public health issue, with over 50% prevalence in China, necessitating new intervention methods beyond existing treatments like low-concentration atropine eye drops [1][2]. Group 1: Current Challenges in Myopia Prevention - Low-concentration atropine effectively delays myopia progression by approximately 60% but only controls axial length growth by about 30%, indicating a significant limitation [2]. - The dual effects of atropine include measurement bias due to its dilation effect and a compensatory response that may lead to pathological elongation of the eyeball [2]. Group 2: Discovery of Crocetin - A groundbreaking study from Japan identified Crocetin as a potent activator of EGR-1, a key transcription factor in regulating cell proliferation and differentiation, which may intervene in myopia progression [3]. - In a mouse model, Crocetin significantly reduced axial length growth compared to the control group [5]. Group 3: Clinical Trials and Efficacy - A clinical study involving 67 children aged 6-12 showed that daily oral administration of 7.5mg Crocetin for six months resulted in a significant increase in choroidal thickness compared to the control group [8][10]. - The increase in choroidal thickness is crucial as it improves retinal metabolic conditions and inhibits scleral hypoxic expansion [10]. Group 4: Mechanisms of Action - Crocetin's effects may be attributed to multiple pathways, including EGR-1 activation, antioxidant stress response, and improved choroidal blood flow [11][13]. - Both spherical equivalent refraction and axial length measurements showed significant improvement in the Crocetin group compared to controls [12]. Group 5: Advantages and Future Prospects - Crocetin offers several advantages over traditional drugs, including its natural origin, safety for long-term use, and multi-target action addressing both axial length and refractive error [14]. - Ongoing multi-center clinical trials in China aim to validate the efficacy of different doses of Crocetin for children, with potential complementary use alongside low-concentration atropine [14]. - The development of precise drug delivery systems, such as nano-sustained release eye drops, may position Crocetin as a key player in altering the course of myopia [15].

Core Viewpoint - The leading ophthalmic drug company, Xingqi Eye Medicine, reported significant growth in its 2024 financial results, driven primarily by the successful launch of its myopia treatment, atropine sulfate eye drops, which has become a key growth engine for the company [1][4]. Financial Performance - In 2024, the company achieved a total revenue of 1.943 billion yuan, marking a year-on-year increase of 32.42% [2]. - The net profit attributable to shareholders reached 338 million yuan, reflecting a growth of 40.84% [2]. - The net profit after deducting non-recurring gains and losses was 347 million yuan, with a growth rate of 44.54% [2]. - The gross profit margin improved to 78.33%, an increase of 0.96 percentage points compared to the previous year [6]. Product Performance - The "myopia miracle drug," atropine sulfate eye drops (marketed as "Mei Ou Pin"), saw its revenue in the eye drop segment surge by 106.08% year-on-year following its approval for use in children aged 6-12 [4][6]. - The company has a diverse product line with 60 approved ophthalmic drug products, of which 38 are included in the medical insurance directory [6]. Market Competition - The market is becoming increasingly competitive, with rivals such as Hengrui Medicine and Zhaoke Ophthalmology nearing the launch of similar products, which could impact Xingqi's market share [3][8]. - Alternative solutions like orthokeratology lenses are also diverting patients, creating a dual challenge for the company [9]. - The company is responding to competition by enhancing its R&D and channel strategies, including advancing clinical trials for different concentrations of atropine eye drops [9]. Strategic Initiatives - The company plans to build a comprehensive service ecosystem to address the competitive landscape in the 300 billion yuan youth myopia prevention market, moving from a single product focus to a platform-based development approach [9].